American Oriental Bioengineering’s (AOB) third quarter earnings per share came in at 13 cents, well below the Zacks Consensus Estimate of 19 cents and 21 cents in the year ago period. The company derives revenues from two operating segments – Manufacturing and Distribution. During the quarter, Manufacturing accounted for more than 95% of the company’s total revenues.

Total revenues increased 11.7% year over year to $78.8 million. American Oriental records Manufacturing revenues from two sources – Pharmaceutical and Nutraceutical products. Both sources recorded an increase of 6.3% to $66 million and 8.2% to $9.2 million, respectively, compared to the third quarter of 2008. The company generated $3.6 million from its Distribution business during the reported quarter.

Revenues from prescription pharmaceutical products increased 22.7% to $29.8 million during the quarter, primarily driven by increased sales of Jinji capsule, Boke and CCXA products, partially offset by decline in sales of Shuanghuanglian injection

...

DELTA, BC - November 5, 2009 - www.InvestorIdeas.com reports the hottest selling investor tools include the mining stocks directory and the renewable energy stocks directory, each directory listing over 900 publicly traded companies on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading Stock Exchanges.

IntercontinentalExchange, Inc. (ICE) reported its third quarter results yesterday.

The company swung to a GAAP net income of $86.9 million or $1.18 per share from a net income of $75 million or $1.04 in the year-ago period. Results came in 3 cents ahead of the Zacks Consensus Estimate of $1.15.

The quarterly results benefited from position limitations on speculators, sweeping regulatory reforms, lower expenses and record futures trading. The upside was also attributable to growth in the company’s core businesses, significant progress from new initiatives and stronger margins.

The company could benefit as more over-the-counter contracts are exchange-traded and cleared, but could suffer if U.S. regulators impose new commodity-market position limits.

Net revenues increased 27.2% year over year to $256.3 million. The growth was primarily attributable to 34% increase in consolidated transaction and clearing fee revenues in the quarter driven primarily by new products, strong trading volumes in ICE's futures and OTC energy segments, continued

...

Volatile price swings seem to be the name of the game in the small-cap world these days – and after hitting record-breaking volatility back in December, many investors have been left wondering when things are going to calm down. But unlike blue-chip stocks, where high price volatility is an unwelcome trend, that same price flux can equal serious profits for small-cap stocks.

Keep this volatility tip in mind and you’ll be well on your way to profiting from the price swings…

It can be nerve-racking to watch a stock pinball. And if you own shares of any penny stock, you have to be able to spot whether or not the stock is taking a turn for the worse. But wild price swings don’t always mean that there’s cause for concern in your small-cap portfolio.

OTC Is Inherently Volatile

Volatility is inherent in any small-cap stock, but that’s especially true of stocks that

...

Today, Nutra Pharma Corp., a biotechnology company that develops treatments for AMN, HIV and Multiple Sclerosis, announced the launch of an over-the-counter pain reliever, Cobroxin, for the treatment of Stage 2 chronic pain. Cobroxin is the first clinically approved OTC pain reliever for Stage 2 pain.

The drug, developed by Nutra Pharma’s subsidiary, ReceptoPharm, will be available as an oral spray. It is designed to treat lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia. It will also be available as a topical gel for treating repetitive stress, arthritis, and joint pain.

Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation, commented, “Cobroxin is a next generation pain reliever that addresses physician and consumer demand for a safer and less costly treatment for chronic pain. Cobroxin provides affordable and accessible pain relief for those without healthcare coverage, for those looking for a safer and effective treatment for pain,

...

Great letter from Jim Sinclair:

Dear Comrades In Golden Arms,

Let’s put on our practical thinking hats. I am inviting opinions from both our academic reader as well as those that believe answers are more accurate when derived by the “follow the money” concept.

The Fed says and statistics support that the majority of the $8.5 trillion in funds injected into the economy in many ways was to protect the US financial community. This has given comfort to the establishment intellectuals that there is no inflationary implication as a result of this massage and unprecedented liquidity injections.

Follow the money approach

The US Federal Reserve made $8.5 trillion available to Wall Street and other entities with OTC derivatives in their inventory. These “assets” have the potential for causing bankruptcy.

It is claimed that the majority of these funds will not have an inflationary impact because of the huge amount of T bills, bonds and note sales

...

Despite a key endorsement by the American Cancer Society for EXACT Science’s (EXAS) stool DNA-based colorectal cancer screening test earlier this year, the stock continues to languish at multi-year lows on light average volumes. EXACT is expected to finalize its FDA protocol for the V2 technology of its test to gain the agency’s approval and also engaged Leerink Swan to explore strategic alternatives over three months ago. In April , the Company submitted its pre-IDE study protocol to the FDA for a de novo 510(k) filing of its V2 technology. I expect the FDA protocol to be finalized soon, resulting in the filing of a 510(k) application with the agency and the potential for a lucrative partnership deal for this test to alleviate funding concerns and bolster the dwindling cash reserves of $9.5 million.

Recent reports suggest that EXACT is now planning to make the latest version of its …

My Vintage Baby, Inc. (OTC: MVBY) recently announced that they have sold $250,000 of senior-secured, fixed-price convertible debentures to a New York institutional investor, Agile Opportunity Fund, LLC. My Vintage Baby engages in the design, production, and sale of clothing and accessories.

David Propis, Agile’s managing director, stated, “My Vintage Baby has undergone a significant balance sheet and operational cleanup over the past year. In my opinion the Company is poised for growth and sustained profitability. Our investment was based on our analysis that MVBY should become profitable within the next year. The Company’s design team, headed by Jessica Wiswall, has the resources necessary to fulfill its mission to create and distribute niche, high-end children’s apparel.”

“I am pleased to announce that we were able to complete the debt transaction convertible at a fixed price with no stipulated registration requirement,” said Jeff Walsh, CEO of My Vintage Baby.

...

Steve Reeves' return on his portfolio is at a positive 8.73% as of May 29th, 2008.  Reeves is our OTC specialist and never pulls the trigger on a stock that costs more than $5.  Review his portfolio of stocks and decide for yourself if you'd like to become a subscriber. Fellow Masters, my articles and stock recommendations are now available on www.WallStNewsletters.com. I look for undervalued securities and the cheaper the price the better.  OTC stocks are my favorite hunting grounds and I never pull the trigger on a stock that costs more than $5 and is worth holding for at least ...